Education
About Us
Working with TipRanks
Follow Us
Allergy Therapeutics PLC (GB:AGY)
LSE:AGY
AGY Stock Chart & Stats
11.80 p
-0.04 p(-0.55%)
At close: 4:00 PM EST
11.80 p
-0.04 p(-0.55%)
Day’s Range― - ―
52-Week Range5.00 p - 12.10 p
Previous CloseN/A
Volume22.64K
Average Volume (3M)460.33K
Market Cap
£728.24M
Enterprise Value574.80M
Total Cash (Recent Filing)£12.79M
Total Debt (Recent Filing)£60.09M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,332,530,000
10 Day Avg. Volume433,490
30 Day Avg. Volume460,334
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£68.00M
Bulls Say, Bears Say
Bulls Say
Focused Allergy Immunotherapy PortfolioA clear product focus on allergy immunotherapy creates a durable commercial niche. Proprietary vaccines and therapy offerings support recurring treatment patterns, foster clinician relationships, and build barriers to entry that can sustain revenue streams and market positioning over months.
Partnerships And Distribution CapabilitiesEstablished partnerships and distributor relationships provide structural commercialization advantages: broader market access, lower go-to-market costs, and potential co-marketing or licensing opportunities. These channels help scale sales and reduce execution risk over the medium term.
Clinical Pipeline And Co-development PotentialAn active clinical program and the prospect of co-development or licensing create durable optionality. Successful trial outcomes or partner-funded programs can unlock new revenue streams, strengthen IP, and de-risk commercialization costs, supporting longer-term growth beyond current product sales.
Bears Say
Declining Revenue And Weak MarginsSustained revenue decline and very large losses undermine operating scalability. Negative margins reduce retained earnings, limit reinvestment capacity into R&D and sales, and increase the likelihood of restructuring or external financing needs that constrain strategic options over months.
Negative Operating And Free Cash FlowPersistent cash burn and sharply deteriorating free cash flow signal limited internal funding capacity. Reliance on external capital to sustain operations raises financing risk, can dilute shareholders, and may curtail pipeline development or commercial expansion in the medium term.
Stressed Balance Sheet And Negative EquityNegative equity and high leverage weaken financial flexibility, tightening access to credit and increasing covenant or refinancing risk. This structural fragility can force asset sales, restrictive financing terms, or dilutive capital raises that impair long-term strategic execution.
Allergy Therapeutics News
AGY FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest share price was 5.00 p and its highest was 12.10 p in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is £728.24M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 30, 2026 which is in 205 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Currently, no data Available
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics (AGY) is a biotechnology company focused on the development and commercialization of innovative allergy immunotherapy products. The company specializes in providing treatments for allergic conditions, primarily targeting pollen, dust mites, and animal allergens. Its core product offerings include allergy vaccines and immunotherapy solutions designed to alleviate symptoms and improve the quality of life for patients suffering from allergies. AGY operates primarily within the healthcare sector, leveraging cutting-edge research to develop effective therapies for allergy sufferers worldwide.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---